ESR1 and breast cancer: A genome-wide association study (GWAS) of breast cancer patients in a phase III trial comparing anastrozole versus exemestane identified a SNP in the second intron of ZNF423 that is associated with recruitment of ER in the presence of 4-hydroxytamoxifen [6].